Oasmia Pharmaceutical Net Income vs. Revenue

OASMYDelisted Stock  USD 0.06  0.00  0.00%   
Taking into consideration Oasmia Pharmaceutical's profitability measurements, Oasmia Pharmaceutical AB may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Oasmia Pharmaceutical's ability to earn profits and add value for shareholders.
For Oasmia Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oasmia Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oasmia Pharmaceutical AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oasmia Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oasmia Pharmaceutical AB over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Please note, there is a significant difference between Oasmia Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oasmia Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oasmia Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Oasmia Pharmaceutical Revenue vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Oasmia Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Oasmia Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Oasmia Pharmaceutical AB is considered to be number one stock in net income category among its peers. It also is rated top company in revenue category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oasmia Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oasmia Pharmaceutical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Oasmia Revenue vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Oasmia Pharmaceutical

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(132.72 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Oasmia Pharmaceutical

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
26.19 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Oasmia Revenue vs Competition

Oasmia Pharmaceutical AB is rated top company in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is now estimated at about 100.06 Billion. Oasmia Pharmaceutical adds roughly 26.19 Million in revenue claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.

Oasmia Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Oasmia Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oasmia Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Oasmia Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Oasmia Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. Vivesto Ab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 17 people.

Oasmia Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Oasmia Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oasmia Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oasmia Pharmaceutical's important profitability drivers and their relationship over time.

Use Oasmia Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oasmia Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oasmia Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Oasmia Pharmaceutical Pair Trading

Oasmia Pharmaceutical AB Pair Trading Analysis

The ability to find closely correlated positions to Oasmia Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oasmia Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oasmia Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oasmia Pharmaceutical AB to buy it.
The correlation of Oasmia Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oasmia Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oasmia Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oasmia Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Oasmia Pharmaceutical position

In addition to having Oasmia Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Advertising Thematic Idea Now

Advertising
Advertising Theme
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Oasmia Pink Sheet

If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas